Navigation Links
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Date:9/23/2011

EAST HANOVER, N.J., Sept. 23, 2011 /PRNewswire/ -- A Phase III study of Afinitor® (everolimus) tablets* in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors. Findings from the trial, known as EXIST-2, were presented today at the International TSC Research Conference in Belfast, Northern Ireland(1).

Tuberous sclerosis complex is a genetic disorder that may cause non-cancerous tumors to form in vital organs, including the brain (SEGAs) and kidney (angiomyolipomas)(3). These kidney tumors occur in up to 80% of patients, usually occurring between the ages of 15 and 30 and increasing in prevalence with age(2,3). Angiomyolipomas are the greatest cause of morbidity and mortality in adult TSC patients, as larger tumors may cause severe bleeding, require surgical intervention or result in kidney failure(2,3). Tumor symptoms may include nausea, vomiting, pain and bleeding(3,6,7).

Results of the 118-patient, randomized, placebo-controlled Phase III EXIST-2 (EXamining everolimus In a Study of TSC) trial showed 42% of patients (33 of 79) experienced a response in the everolimus arm versus 0% of patients (0 of 39) on placebo (p<0.0001) based on best overall response rate(1). These results add to the recent positive Phase III data from a separate trial in patients with TSC, which demonstrated reduction in the size of non-cancerous brain tumors (SEGAs) with everolimus(5).

"For the first time, a large placebo-controlled study has focused specifically on angiomyolipomas in TSC patients, an area with clear unmet need," said Dr. John Bissler, lead study author and Clark D. West Endowed Chair of Nephrology at Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. "In addition to the tumor reduction seen with everolimus in this trial, s
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
4. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
5. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
6. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
7. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
8. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
11. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin ... company that specializes in patented biopharmaceutical, modernized traditional ... ingredients (API) today announced that the Company achieved ... Good Manufacturing Practice (GMP) certificate of TPI,s Qionglai ... Administration,s (CFDA). The public notice period is a ...
(Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... BRANFORD, Connecticut, June 15, 2011 , ... has killed dozens and,hospitalized thousands across Europe has been ... to generate the,"most accurate and detailed genetic analysis to ... ] ,The sequencing was performed by scientists at the ...
... Systems, Inc. (NYSE: VAR ), the world,s ... radiotherapy, announced today it has received Shonin approval from ... to market the TrueBeam™ system for image-guided radiotherapy and ... breast, prostate, head and neck, and other types of ...
Cached Medicine Technology:Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date 2Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date 3TrueBeam™ System for Non-Invasive Image-Guided Cancer Treatment Receives Shonin Approval 2TrueBeam™ System for Non-Invasive Image-Guided Cancer Treatment Receives Shonin Approval 3
(Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- The risk of ... holidays, so you need to be extra cautious, an ... we see a significant increase in patients coming in ... the Suffolk County Volunteer Firefighters Burn Center of Stony ... should be full of joy, but if not careful, ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... a "fountain of youth" drug that can delay the effects ... new study suggests. Seniors received a significant boost to ... genetic signaling pathway linked to aging and immune function, researchers ... experimental medication, a version of the drug rapamycin, improved the ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as part ... mobile applications on the iOS, Android, and Windows markets. Andrew ... the app review and shared with viewers how this is ... old saying goes, “A picture says a thousand words.” It’s ... a single image, because each picture holds a unique and ...
(Date:12/25/2014)... Each year trauma accounts for approximately ... admissions across the nation (according to the Centers ... National Hospital Ambulatory Medical Care Survey collected data ... 2010. They estimated that there were between 3.5 and ... primary diagnosis of broken bone or fracture. , ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 Over 700 ... to their local communities. That is 700 smiling little ... single gift. Additionally over $6000 in monetary donations was ... offset some of the expenses they incur through the ... drive were A Child's Haven , Shrine's Children's ...
Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife Donates Over 700 Toys This Year 2
... News) -- Exposure to secondhand smoke could affect hearing ... loss during adolescence, a new study indicates. These ... exposed to secondhand smoke, the researchers warned. Roughly ... exposed to secondhand smoke, reported the study,s authors. These ...
... HealthDay Reporter , MONDAY, July 18 (HealthDay ... blood pressure modestly among hypertensive patients, a small, new ... refined carbohydrates -- such as white bread and white ... protein "might be an important component of nutrition intervention ...
... JULY 18, 2011 Registration is now open for ... the Cardiovascular Research Foundation, which will return to San ... year, groundbreaking scientific advances in interventional cardiology presented at ... cause of death in the United States, is viewed ...
... journal Science Signaling Van Andel Research Institute ... anti-malaria drug chloroquine represses inflammation, which may provide a ... multitude of autoimmune diseases such as arthritis, multiple sclerosis, ... anti-malaria drug that inhibits the growth of parasites. For ...
... Researchers at Mount Sinai School of Medicine have identified how ... diabetes, also possibly kills nerve cells in the brain, thereby ... the generation of amyloid-beta (Abeta) in the brain. Abeta plays ... researchers previously linked SorCS1 to Alzheimer,s disease and identified where ...
... pace of translating science into real-life solutions for patients ... Health to expand its work over the next five ... (CTSI) is among 10 institutes nationwide to receive the ... first five years of the NIH,s Clinical and Translational ...
Cached Medicine News:Health News:Secondhand Smoke Linked to Hearing Loss in Teens 2Health News:Small Study Suggests Milk, Soy Proteins Lower Blood Pressure Modestly 2Health News:Small Study Suggests Milk, Soy Proteins Lower Blood Pressure Modestly 3Health News:Innovations in cardiovascular therapies and treatments will be presented at TCT 2011 2Health News:Chloroquine finding may lead to treatments for arthritis, cancer and other diseases 2Health News:Chloroquine finding may lead to treatments for arthritis, cancer and other diseases 3Health News:Researchers identify how a gene linked to both Alzheimer's disease and type 2 diabetes works 2Health News:UCSF receives $112 million to help translate science into cures 2Health News:UCSF receives $112 million to help translate science into cures 3Health News:UCSF receives $112 million to help translate science into cures 4
When You Need Optimal Patient Comfort with Minimal Weight at a Nonunion Site...Demand The OrthoPak Noninvasive Bone Growth Stimulator., ,Most Appropriate for the Proximal Femur, Metatarsal/Tarsal...
... Siemens Medical Solutions introduces its new ... system with intuitive patient data management ... lithotripter and urological table. Lithoskop is ... urodiagnostics that covers all applications like ...
... bone growth stimulator for the treatment of ... bone growth stimulator is a useful adjunct ... is already planned or when patient compliance ... is totally surgically implanted, patients are assured ...
... cataract surgery following refractive surgery grows larger ... for surgeons, as calculating IOL power for ... power following RK, ALK, PRK and LASIK ... or topography. For example, keratometry and simulated ...
Medicine Products: